SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

UPLOAD Filing

TAO Synergies Inc.
Date: July 15, 2025 · CIK: 0001571934 · Accession: 0000000000-25-007425

Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-288647

Date
July 15, 2025
Author
Division of
Form
UPLOAD
Company
TAO Synergies Inc.

Letter

Re: TAO Synergies Inc. Registration Statement on Form S-3 Filed July 11, 2025 File No. 333-288647 Dear Robert Weinstein:

July 15, 2025

Robert Weinstein Chief Financial Officer TAO Synergies Inc. 1185 Avenue of the Americas, 3rd Floor New York, NY 10036

This is to advise you that we have not reviewed and will not review your registration statement.

Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.

Please contact Doris Stacey Gama at 202-551-3188 with any questions.

Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Daniel A. Bagliebter, Esq.

Show Raw Text
<DOCUMENT>
<TYPE>TEXT-EXTRACT
<SEQUENCE>2
<FILENAME>filename2.txt
<TEXT>
 July 15, 2025

Robert Weinstein
Chief Financial Officer
TAO Synergies Inc.
1185 Avenue of the Americas, 3rd Floor
New York, NY 10036

 Re: TAO Synergies Inc.
 Registration Statement on Form S-3
 Filed July 11, 2025
 File No. 333-288647
Dear Robert Weinstein:

 This is to advise you that we have not reviewed and will not review your
registration
statement.

 Please refer to Rules 460 and 461 regarding requests for acceleration.
We remind you
that the company and its management are responsible for the accuracy and
adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action
by the staff.

 Please contact Doris Stacey Gama at 202-551-3188 with any questions.

 Sincerely,

 Division of
Corporation Finance
 Office of Life
Sciences
cc: Daniel A. Bagliebter, Esq.
</TEXT>
</DOCUMENT>